Skip to content

US · GCTK · MEDICAL - INSTRUMENTS & SUPPLIES

GlucoTrack, Inc. (GCTK) intrinsic value and stock valuation

$0.45as of 2026-11-21 · Mkt cap 245.25K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

GlucoTrack, Inc. DCF and intrinsic value

InvestorsCraft values GCTK with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GCTK’s statements →

GlucoTrack, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Rutherford, NJ 07070 glucotrack.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-19.39M
20112025
Free cash flow
-$-15.34M
20112025
Total equity
$2.83M-20.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-16.09M-$-14.55M-$-7.1M-$-4.43M-$-4.04M
Net income-$-19.39M-$-22.6M-$-7.1M-$-4.43M-$-4.07M
EPSd-$-21.54M-$-61.08M-$-33.81M-$-29.53M-$-27.13M
Operating cash flow-$-15.24M-$-12.49M-$-6.56M-$-3.73M-$-3.77M
Capital expenditure-$-100K-$-100K$0.00-$0.00-$-10K
Free cash flow-$-15.34M-$-12.59M-$-6.56M-$-3.73M-$-3.77M
Total assets$7.84M$5.93M$4.91M$2.44M$6.26M
Total debt$30K$270K$200K$200K$250K
Net debt-$-7.35M-$-5.35M-$-4.3M-$-2.12M-$-5.81M
Total equity$2.83M-$-13M$3.2M$1.23M$5.16M
Cash and short-term investments$7.38M$5.62M$4.49M$2.31M$6.06M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$9.81M$9.5M$4.7M$1.97M$1.81M
Selling, general and administrative expenses$6.28M$5.05M$2.4M$2.45M$2.12M
Other expenses$0.00$0.00$0.00$10K$110K
Operating expenses$16.1M$14.6M$7.1M$4.43M$4.04M
Cost and expenses$16.1M$14.6M$7.1M$4.43M$4.04M
Interest income$0.00$60K$10K$10K$30K
Interest expense$0.00$630K$0.00$0.00$0.00
Depreciation and amortization$40K$40K$10K$20K$40K
Ebitda-$-19.35M-$-21.93M-$-7.08M-$-4.41M-$-3.94M
Operating income-$-16.09M-$-14.55M-$-7.1M-$-4.43M-$-4.04M
Total other income/expenses, net-$-3.3M-$-8.05M$10K-$0.00-$-30K
Income before tax-$-19.39M-$-22.6M-$-7.1M-$-4.43M-$-4.07M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-19.39M-$-22.6M-$-7.1M-$-4.43M-$-4.07M
Weighted average shares outstanding$900K$370K$180K$150K$150K
Weighted average diluted shares outstanding$900K$370K$210K$150K$150K
Balance sheet
20252024202320222021
Cash and short-term investments$7.38M$5.62M$4.49M$2.31M$6.06M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$7.67M$5.77M$4.87M$2.38M$6.11M
Property, plant and equipment, net$170K$150K$30K$40K$110K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$10K$0.00$10K$50K
Total non-current assets$170K$160K$40K$60K$160K
Total assets$7.84M$5.93M$4.91M$2.44M$6.26M
Accounts payable$1.32M$990K$840K$670K$630K
Short-term debt$30K$30K$0.00$0.00$20K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.77M$1.27M$1.51M$1.01M$880K
Long-term debt$10K$240K$200K$200K$230K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$240K$17.7M$200K$200K$230K
Capital lease obligations$0.00$60K$0.00$0.00$40K
Total liabilities$5.01M$18.9M$1.71M$1.21M$1.11M
Common stock$0.00$0.00$20K$10K$10K
Retained earnings-$-151.84M-$-132.45M-$-109.85M-$-101.9M-$-97.47M
Accumulated other comprehensive income (loss)$40K-$-10K$60K$20K-$-10K
Total equity$2.83M-$-13M$3.2M$1.23M$5.16M
Total investments$0.00$10K$0.00$10K$50K
Total debt$30K$270K$200K$200K$250K
Net debt-$-7.35M-$-5.35M-$-4.3M-$-2.12M-$-5.81M
Cash flow statement
20252024202320222021
Net income-$-19.39M-$-22.6M-$-7.1M-$-4.43M-$-4.07M
Depreciation and amortization$40K$40K$10K$20K$40K
Stock-based compensation$210K$170K$280K$440K$220K
Change in working capital$210K$70K$190K$180K-$-50K
Accounts receivable$0.00$0.00$0.00$0.00$70K
Inventory$0.00$0.00$0.00$0.00$290K
Accounts payable$330K$260K$170K$70K-$-260K
Net cash provided by operating activities-$-15.24M-$-12.49M-$-6.56M-$-3.73M-$-3.77M
Investments in property, plant and equipment-$-100K-$-100K$0.00-$0.00-$-10K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-100K-$-100K$0.00$0.00-$0.00
Common stock issued$14M$9.28M$8.73M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$17M$13.7M$8.73M$0.00$0.00
Net change in cash$1.76M$1.12M$2.17M-$-3.78M-$-3.77M
Cash at end of period$7.38M$5.63M$4.5M$2.33M$6.11M
Operating cash flow-$-15.24M-$-12.49M-$-6.56M-$-3.73M-$-3.77M
Capital expenditure-$-100K-$-100K$0.00-$0.00-$-10K
Free cash flow-$-15.34M-$-12.59M-$-6.56M-$-3.73M-$-3.77M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About GlucoTrack, Inc.

        Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems. Their primary offering, the GlucoTrack device, enables individuals with diabetes or pre-diabetes to painlessly check their blood glucose levels. This technology is available to customers both in Israel and across the globe. The company, founded in 2001, operated under the name Integrity Applications, Inc. until it officially rebranded to GlucoTrack, Inc. in November 2021.

        CEO
        Erik Emerson
        Employees
        15
        Beta
        0.66

        Explore

        Frequently asked questions

        What is the intrinsic value of GlucoTrack, Inc. (GCTK)?

        InvestorsCraft does not currently publish an intrinsic value for GCTK. How the IC value is calculated.

        Is GCTK undervalued?

        InvestorsCraft does not publish an undervaluation signal for GCTK at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.